This page has only limited features, please log in for full access.
Background The long-term sequalae of COVID-19 remain poorly characterised. We assessed persistent symptoms in previously hospitalised patients with COVID-19 and assessed potential risk factors. Methods Data were collected from patients discharged from 4 hospitals in Moscow, Russia between April 8 and July 10, 2020. Participants were interviewed via telephone using an ISARIC Long-term Follow-up Study questionnaire. Results 2,649 of 4755 (56%) discharged patients were successfully evaluated, at median 218 (IQR 200, 236) days post-discharge. COVID-19 diagnosis was clinical in 1291 and molecular in 1358. Most cases were mild, but 902 (34%) required supplemental oxygen and 68 (2.6%) needed ventilatory support. Median age was 56 years (IQR 46, 66) and 1,353 (51.1%) were women. Persistent symptoms were reported by 1247 (47.1%) participants, with fatigue (21.2%), shortness of breath (14.5%) and forgetfulness (9.1%) the most common symptoms and chronic fatigue (25%) and respiratory (17.2%) the most common symptom categories. Female sex was associated with any persistent symptom category OR 1.83 (95% CI 1.55 to 2.17) with association being strongest for dermatological (3.26, 2.36 to 4.57) symptoms. Asthma and chronic pulmonary disease were not associated with persistent symptoms overall, but asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18), and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Conclusions Almost half of adults admitted to hospital due to COVID-19 reported persistent symptoms 6 to 8 months after discharge. Fatigue and respiratory symptoms were most common, and female sex was associated with persistent symptoms.
Daniel Munblit; Polina Bobkova; Ekaterina Spiridonova; Anastasia Shikhaleva; Aysylu Gamirova; Oleg Blyuss; Nikita Nekliudov; Polina Bugaeva; Margarita Andreeva; Audrey DunnGalvin; Pasquale Comberiati; Christian Apfelbacher; Jon Genuneit; Sergey Avdeev; Valentina Kapustina; Alla Guekht; Victor Fomin; Andrey A Svistunov; Peter Timashev; Vladislav S Subbot; Valery V Royuk; Thomas M Drake; Sarah Wulf Hanson; Laura Merson; Gail Carson; Peter Horby; Louise Sigfrid; Janet T Scott; Malcolm G Semple; John O Warner; Theo Vos; Piero Olliaro; Petr Glybochko; Denis Butnaru; Elina Abdeeva; Nikol Alekseeva; Elena Antsiferova; Elena Artigas; Anastasiia Bairashevskaia; Anna Belkina; Vadim Bezrukov; Semyon Bordyugov; Maria Bratukhina; Jessica Chen; Salima Deunezhewa; Khalisa Elifkhanova; Anastasia Ezhova; Yulia Filippova; Aleksandra Frolova; Julia Ganieva; Anastasia Gorina; Yulia Kalan; Bogdan Kirillov; Mariia Korgunova; Alexandra Krupina; Anna Kuznetsova; Ekaterina Listovskaia; Margarita Mikheeva; Aigun Mursalova; Marina Ogandzhanova; Callum Parr; Mikhail Rumyantsev; Denis Smirnov; Nataliya Shishkina; Yasmin El‐Taravi; Maria Varaksina; Maria Vodianova; Anna Zezyulina; Sechenov StopCOVID Research Team. Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID‐19. Clinical & Experimental Allergy 2021, 1 .
AMA StyleDaniel Munblit, Polina Bobkova, Ekaterina Spiridonova, Anastasia Shikhaleva, Aysylu Gamirova, Oleg Blyuss, Nikita Nekliudov, Polina Bugaeva, Margarita Andreeva, Audrey DunnGalvin, Pasquale Comberiati, Christian Apfelbacher, Jon Genuneit, Sergey Avdeev, Valentina Kapustina, Alla Guekht, Victor Fomin, Andrey A Svistunov, Peter Timashev, Vladislav S Subbot, Valery V Royuk, Thomas M Drake, Sarah Wulf Hanson, Laura Merson, Gail Carson, Peter Horby, Louise Sigfrid, Janet T Scott, Malcolm G Semple, John O Warner, Theo Vos, Piero Olliaro, Petr Glybochko, Denis Butnaru, Elina Abdeeva, Nikol Alekseeva, Elena Antsiferova, Elena Artigas, Anastasiia Bairashevskaia, Anna Belkina, Vadim Bezrukov, Semyon Bordyugov, Maria Bratukhina, Jessica Chen, Salima Deunezhewa, Khalisa Elifkhanova, Anastasia Ezhova, Yulia Filippova, Aleksandra Frolova, Julia Ganieva, Anastasia Gorina, Yulia Kalan, Bogdan Kirillov, Mariia Korgunova, Alexandra Krupina, Anna Kuznetsova, Ekaterina Listovskaia, Margarita Mikheeva, Aigun Mursalova, Marina Ogandzhanova, Callum Parr, Mikhail Rumyantsev, Denis Smirnov, Nataliya Shishkina, Yasmin El‐Taravi, Maria Varaksina, Maria Vodianova, Anna Zezyulina, Sechenov StopCOVID Research Team. Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID‐19. Clinical & Experimental Allergy. 2021; ():1.
Chicago/Turabian StyleDaniel Munblit; Polina Bobkova; Ekaterina Spiridonova; Anastasia Shikhaleva; Aysylu Gamirova; Oleg Blyuss; Nikita Nekliudov; Polina Bugaeva; Margarita Andreeva; Audrey DunnGalvin; Pasquale Comberiati; Christian Apfelbacher; Jon Genuneit; Sergey Avdeev; Valentina Kapustina; Alla Guekht; Victor Fomin; Andrey A Svistunov; Peter Timashev; Vladislav S Subbot; Valery V Royuk; Thomas M Drake; Sarah Wulf Hanson; Laura Merson; Gail Carson; Peter Horby; Louise Sigfrid; Janet T Scott; Malcolm G Semple; John O Warner; Theo Vos; Piero Olliaro; Petr Glybochko; Denis Butnaru; Elina Abdeeva; Nikol Alekseeva; Elena Antsiferova; Elena Artigas; Anastasiia Bairashevskaia; Anna Belkina; Vadim Bezrukov; Semyon Bordyugov; Maria Bratukhina; Jessica Chen; Salima Deunezhewa; Khalisa Elifkhanova; Anastasia Ezhova; Yulia Filippova; Aleksandra Frolova; Julia Ganieva; Anastasia Gorina; Yulia Kalan; Bogdan Kirillov; Mariia Korgunova; Alexandra Krupina; Anna Kuznetsova; Ekaterina Listovskaia; Margarita Mikheeva; Aigun Mursalova; Marina Ogandzhanova; Callum Parr; Mikhail Rumyantsev; Denis Smirnov; Nataliya Shishkina; Yasmin El‐Taravi; Maria Varaksina; Maria Vodianova; Anna Zezyulina; Sechenov StopCOVID Research Team. 2021. "Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID‐19." Clinical & Experimental Allergy , no. : 1.
Nutraceuticals, including vitamin D, vitamin A, zinc, lactoferrin, polyphenols coenzyme Q, magnesium, and selenium, are implicated in the modulation of the complex molecular pathways involved in the immune response against viral pathogens. A common element of the activity of nutraceuticals is their ability to enhance the innate immune response against pathogens by acting on the major cellular subsets and inducing the release of pro-inflammatory cytokines and antimicrobial peptides. In some cases, this action is accompanied by a direct antimicrobial effect, as evidenced in the specific case of lactoferrin. Furthermore, nutraceuticals act through complex molecular mechanisms to minimize the damage caused by the activation of the immune system against pathogens, reducing the oxidative damage, influencing the antigen presentation, enhancing the differentiation and proliferation of regulatory T cells, driving the differentiation of lymphocyte subsets, and modulating the production of pro-inflammatory cytokines. In this paper, we review the main molecular mechanisms responsible for the immunomodulatory function of nutraceuticals, focusing on the most relevant aspects for the prevention and treatment of viral infections.
Giorgio Costagliola; Giulia Nuzzi; Erika Spada; Pasquale Comberiati; Elvira Verduci; Diego Peroni. Nutraceuticals in Viral Infections: An Overview of the Immunomodulating Properties. Nutrients 2021, 13, 2410 .
AMA StyleGiorgio Costagliola, Giulia Nuzzi, Erika Spada, Pasquale Comberiati, Elvira Verduci, Diego Peroni. Nutraceuticals in Viral Infections: An Overview of the Immunomodulating Properties. Nutrients. 2021; 13 (7):2410.
Chicago/Turabian StyleGiorgio Costagliola; Giulia Nuzzi; Erika Spada; Pasquale Comberiati; Elvira Verduci; Diego Peroni. 2021. "Nutraceuticals in Viral Infections: An Overview of the Immunomodulating Properties." Nutrients 13, no. 7: 2410.
Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with Covid-19 and associated risk factors. Methods This is a prospective cohort study of children (18 years old and younger) admitted with confirmed Covid-19 to Z.A. Bashlyaeva Children's Municipal Clinical Hospital in Moscow, Russia. Children admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and August 26, 2020, were included. Telephone interview using the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Covid-19 Health and Wellbeing paediatric follow up survey. Persistent symptoms (>5 months) were further categorised by system(s) involved. Findings Overall, 518 of 853 (61%) of eligible children were available for the follow-up assessment and included in the study. Median age was 10.4 years (IQR, 3-15.2) and 270 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%,) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: age "6-11 years" (odds ratio 2.74 (95% confidence interval 1.37 to 5.75) and "12-18 years" (2.68, 1.41 to 5.4), and a history of allergic diseases (1.67, 1.04 to 2.67). Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multi-system involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up. Our findings highlight the need for replication and further investigation of potential mechanisms as well as clinical support to improve long term outcomes in children. Funding None.
Ismail M Osmanov; Ekaterina Spiridonova; Polina Bobkova; Aysylu Gamirova; Anastasia Shikhaleva; Margarita Andreeva; Oleg Blyuss; Yasmin El-Taravi; Audrey DunnGalvin; Pasquale Comberiati; Diego G Peroni; Christian Apfelbacher; Jon Genuneit; Lyudmila Mazankova; Alexandra Miroshina; Evgeniya Chistyakova; Elmira Samitova; Svetlana Borzakova; Elena Bondarenko; Anatoliy A Korsunskiy; Irina Konova; Sarah Wulf Hanson; Gail Carson; Louise Sigfrid; Janet T Scott; Matthew Greenhawt; Elizabeth A Whittaker; Elena Garralda; Olivia Swann; Danilo Buonsenso; Dasha E Nicholls; Frances Simpson; Christina Jones; Malcolm G Semple; John O Warner; Theo Vos; Piero Olliaro; Daniel Munblit; Sechenov StopCOVID Research Team. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. 2021, 1 .
AMA StyleIsmail M Osmanov, Ekaterina Spiridonova, Polina Bobkova, Aysylu Gamirova, Anastasia Shikhaleva, Margarita Andreeva, Oleg Blyuss, Yasmin El-Taravi, Audrey DunnGalvin, Pasquale Comberiati, Diego G Peroni, Christian Apfelbacher, Jon Genuneit, Lyudmila Mazankova, Alexandra Miroshina, Evgeniya Chistyakova, Elmira Samitova, Svetlana Borzakova, Elena Bondarenko, Anatoliy A Korsunskiy, Irina Konova, Sarah Wulf Hanson, Gail Carson, Louise Sigfrid, Janet T Scott, Matthew Greenhawt, Elizabeth A Whittaker, Elena Garralda, Olivia Swann, Danilo Buonsenso, Dasha E Nicholls, Frances Simpson, Christina Jones, Malcolm G Semple, John O Warner, Theo Vos, Piero Olliaro, Daniel Munblit, Sechenov StopCOVID Research Team. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. . 2021; ():1.
Chicago/Turabian StyleIsmail M Osmanov; Ekaterina Spiridonova; Polina Bobkova; Aysylu Gamirova; Anastasia Shikhaleva; Margarita Andreeva; Oleg Blyuss; Yasmin El-Taravi; Audrey DunnGalvin; Pasquale Comberiati; Diego G Peroni; Christian Apfelbacher; Jon Genuneit; Lyudmila Mazankova; Alexandra Miroshina; Evgeniya Chistyakova; Elmira Samitova; Svetlana Borzakova; Elena Bondarenko; Anatoliy A Korsunskiy; Irina Konova; Sarah Wulf Hanson; Gail Carson; Louise Sigfrid; Janet T Scott; Matthew Greenhawt; Elizabeth A Whittaker; Elena Garralda; Olivia Swann; Danilo Buonsenso; Dasha E Nicholls; Frances Simpson; Christina Jones; Malcolm G Semple; John O Warner; Theo Vos; Piero Olliaro; Daniel Munblit; Sechenov StopCOVID Research Team. 2021. "Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study." , no. : 1.
Background The long-term sequalae of COVID-19 remain poorly characterised. In this study, we aimed to assess long-standing symptoms (LS) (symptoms lasting from the time of discharge) in previously hospitalised patients with COVID-19 and assess associated risk factors. Methods This is a longitudinal cohort study of adults (≥18 years of age) with clinically diagnosed or laboratory-confirmed COVID-19 admitted to Sechenov University Hospital Network in Moscow, Russia. Data were collected from patients discharged between April 8 and July 10, 2020. Participants were interviewed via telephone using Tier 1 ISARIC Long-term Follow-up Study CRF and the WHO CRF for Post COVID conditions. Reported symptoms were further categorised based on the system(s) involved. Additional information on dyspnoea, quality of life and fatigue was collected using validated instruments. Multivariable logistic regressions were performed to investigate risk factors for development of LS categories. Findings Overall, 2,649 of 4,755 patients discharged from the hospitals were available for the follow-up and included in the study. The median age of the patients was 56 years (IQR, 46–66) and 1,353 (51.1%) were women. The median follow-up time since hospital discharge was 217.5 (200.4-235.5) days. At the time of the follow-up interview 1247 (47.1%) participants reported LS. Fatigue (21.2%, 551/2599), shortness of breath (14.5%, 378/2614) and forgetfulness (9.1%, 237/2597) were the most common LS reported. Chronic fatigue (25%, 658/2593) and respiratory (17.2% 451/2616) were the most common LS categories. with reporting of multi-system involvement (MSI) less common (11.3%; 299). Female sex was associated with LS categories of chronic fatigue with an odds ratio of 1.67 (95% confidence interval 1.39 to 2.02), neurological (2.03, 1.60 to 2.58), mood and behaviour (1.83, 1.41 to 2.40), dermatological (3.26, 2.36 to 4.57), gastrointestinal (2.50, 1.64 to 3.89), sensory (1.73, 2.06 to 2.89) and respiratory (1.31, 1.06 to 1.62). Pre-existing asthma was associated with neurological (1.95, 1.25 to 2.98) and mood and behavioural changes (2.02, 1.24 to 3.18) and chronic pulmonary disease was associated with chronic fatigue (1.68, 1.21 to 2.32). Interpretation 6 to 8 months after acute infection episode almost a half of patients experience symptoms lasting since hospital discharge. One in ten individuals experiences MSI. Female sex is the main risk factor for majority of the LS categories. chronic pulmonary disease is associated with a higher risk of chronic fatigue development, and asthma with neurological and mood and behaviour changes. Individuals with LS and MSI should be the main target for future research and intervention strategies. Funding This study is supported by Russian Fund for Basic Research and UK Embassy in Moscow. The ISARIC work is supported by grants from: the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], EU Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) [FP7 project 602525] This research was funded in part, by the Wellcome Trust. The views expressed are those of the authors and not necessarily those of the DID, NIHR, Wellcome Trust or PHE. Research in context Evidence before this study Evidence suggests that COVID-19 may result in short- and long-term consequences to health. Most studies do not provide definitive answers due to a combination of short follow-up (2-3 months), small sample size, and use of non-standardised tools. There is a need to study the longer-term health consequences of previously hospitalised patients with COVID-19 infection and to identify risk factors for sequalae. Added value of this study To our knowledge, this is the largest cohort study (n=2,649) with the longest follow-up since hospital discharge (6-8 months) of previously hospitalised adult patients. We found that 6-8 months after discharge from the hospital, around a half (47.1%) of patients reported at least one long-standing symptom since discharge. Once categories of symptoms were assessed, chronic fatigue and respiratory problems were the most frequent clusters of long-standing symptoms in our patients. Of those patients having long-term symptoms, a smaller proportion (11.3%) had multisystem involvement, with three or more categories of long-standing symptoms present. Although most patients developed symptoms since discharge, a smaller number of individuals experienced symptom beginning symptom appearing weeks or months after the acute phase. Female sex was a predictor for most of the symptom categories at the time of the follow-up interview, with chronic pulmonary disease associated with chronic fatigue-related symptoms, and asthma with a higher risk of neurological symptoms, mood and behaviour problems. Implications of all the available evidence The majority of patients experienced long-lasting symptoms 6 to 8 months after hospital discharge and almost half reported at least one long-standing symptom, with chronic fatigue and respiratory problems being the most frequent. A smaller number reported multisystem impacts with three or more long-standing categories present at follow-up. A higher risk was found for women, for chronic pulmonary disease with chronic fatigue, and neurological symptoms and mood and behaviour problems with asthma. Patterns of the symptom development following COVID-19 should be further investigated in future research.
Daniel Munblit; Polina Bobkova; Ekaterina Spiridonova; Anastasia Shikhaleva; Aysylu Gamirova; Oleg Blyuss; Nikita Nekliudov; Polina Bugaeva; Margarita Andreeva; Audrey DunnGalvin; Pasquale Comberiati; Christian Apfelbacher; Jon Genuneit; Sergey Avdeev; Valentina Kapustina; Alla Guekht; Victor Fomin; Andrey A Svistunov; Peter Timashev; Thomas M Drake; Sarah Wulf Hanson; Laura Merson; Peter Horby; Louise Sigfrid; Janet T Scott; Malcolm G Semple; John O Warner; Theo Vos; Piero Olliaro; Petr Glybochko; Denis Butnaru; Sechenov StopCOVID Research Team. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. 2021, 1 .
AMA StyleDaniel Munblit, Polina Bobkova, Ekaterina Spiridonova, Anastasia Shikhaleva, Aysylu Gamirova, Oleg Blyuss, Nikita Nekliudov, Polina Bugaeva, Margarita Andreeva, Audrey DunnGalvin, Pasquale Comberiati, Christian Apfelbacher, Jon Genuneit, Sergey Avdeev, Valentina Kapustina, Alla Guekht, Victor Fomin, Andrey A Svistunov, Peter Timashev, Thomas M Drake, Sarah Wulf Hanson, Laura Merson, Peter Horby, Louise Sigfrid, Janet T Scott, Malcolm G Semple, John O Warner, Theo Vos, Piero Olliaro, Petr Glybochko, Denis Butnaru, Sechenov StopCOVID Research Team. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. . 2021; ():1.
Chicago/Turabian StyleDaniel Munblit; Polina Bobkova; Ekaterina Spiridonova; Anastasia Shikhaleva; Aysylu Gamirova; Oleg Blyuss; Nikita Nekliudov; Polina Bugaeva; Margarita Andreeva; Audrey DunnGalvin; Pasquale Comberiati; Christian Apfelbacher; Jon Genuneit; Sergey Avdeev; Valentina Kapustina; Alla Guekht; Victor Fomin; Andrey A Svistunov; Peter Timashev; Thomas M Drake; Sarah Wulf Hanson; Laura Merson; Peter Horby; Louise Sigfrid; Janet T Scott; Malcolm G Semple; John O Warner; Theo Vos; Piero Olliaro; Petr Glybochko; Denis Butnaru; Sechenov StopCOVID Research Team. 2021. "Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study." , no. : 1.
Purpose of review Fractional concentration of Nitric Oxide in the exhaled air (FeNO) is a moderately good biomarker of type-2 airway inflammation, and its measurement is feasible also in children. The available evidence is still not enough to support the routine use of FeNO to diagnose or manage asthma in every patient in clinical practice. However, its role in identifying asthma with eosinophilic inflammation is of particular interest in the management of severe asthma. Recent findings In healthy subjects, FeNO levels increase with age and height, particularly in males, and are also influenced by ethnicity. FeNO measurement can support asthma diagnosis and help in predicting asthma development later in life in young children with recurrent wheezing. FeNO-guided asthma management is effective in reducing asthma exacerbations but may result in a higher daily dose of inhaled corticosteroids. FeNO can also be used as a marker to evaluate adherence to asthma treatment and predict response to different biologicals, especially Omalizumab and Dupilumab. Summary This review outlines recent data on the application of FeNO in childhood-onset asthma diagnosis and management, as well as in phenotyping subjects with severe asthma who may benefit from monoclonal antibodies administration.
Maria Di Cicco; Diego Giampietro Peroni; Vincenzo Ragazzo; Pasquale Comberiati. Application of exhaled nitric oxide (FeNO) in pediatric asthma. Current Opinion in Allergy & Clinical Immunology 2021, 21, 151 -158.
AMA StyleMaria Di Cicco, Diego Giampietro Peroni, Vincenzo Ragazzo, Pasquale Comberiati. Application of exhaled nitric oxide (FeNO) in pediatric asthma. Current Opinion in Allergy & Clinical Immunology. 2021; 21 (2):151-158.
Chicago/Turabian StyleMaria Di Cicco; Diego Giampietro Peroni; Vincenzo Ragazzo; Pasquale Comberiati. 2021. "Application of exhaled nitric oxide (FeNO) in pediatric asthma." Current Opinion in Allergy & Clinical Immunology 21, no. 2: 151-158.
Purpose of review Asthma is a chronic inflammatory airway disorder that can involve the entire bronchial tree. Increasing evidence shows that ventilation heterogeneity and small airway dysfunction are relevant factors in the pathogenesis of asthma and represent a hallmark in adults with persistent asthma. Little is known about the contribution of peripheral airway impairment in paediatric asthma, mainly due to the inaccessibility to evaluation by noninvasive techniques, which have only been widely available in recent years. Recent findings Emerging evidence suggests that small airways are affected from the early stages of the disease in childhood-onset asthma. Conventional lung function measurement, using spirometry, is unable to sensitively evaluate small airway function and may become abnormal only once there is a significant burden of disease. Recent studies suggest that chronic inflammation and dysfunction in the small airways, as detected with new advanced techniques, are risk factors for asthma persistence, asthma severity, worse asthma control and loss of pulmonary function with age, both in adults and children. Knowing the extent of central and peripheral airway involvement is clinically relevant to achieve asthma control, reduce bronchial hyper-responsiveness and monitor response to asthma treatment. Summary This review outlines the recent evidence on the role of small airway dysfunction in paediatric asthma development and control, and addresses how the use of new diagnostic techniques available in outpatient clinical settings, namely impulse oscillometry and multiple breath washout, could help in the early detection of small airway impairment in children with preschool wheezing and school-age asthma and potentially guide asthma treatment.
Marcello Cottini; Carlo Lombardi; Alvise Berti; Pasquale Comberiati. Small-airway dysfunction in paediatric asthma. Current Opinion in Allergy & Clinical Immunology 2021, 21, 128 -134.
AMA StyleMarcello Cottini, Carlo Lombardi, Alvise Berti, Pasquale Comberiati. Small-airway dysfunction in paediatric asthma. Current Opinion in Allergy & Clinical Immunology. 2021; 21 (2):128-134.
Chicago/Turabian StyleMarcello Cottini; Carlo Lombardi; Alvise Berti; Pasquale Comberiati. 2021. "Small-airway dysfunction in paediatric asthma." Current Opinion in Allergy & Clinical Immunology 21, no. 2: 128-134.
Atopic dermatitis is one of the most frequent chronic skin diseases worldwide and often develops within the first few years of life. Recent advancements in our knowledge of its pathophysiology have brought to light the role of genetic predisposition and environmental triggers. With the increasing prevalence of allergic diseases, there is a strong need for a better understanding of the various modifiable eliciting factors of such conditions. The concomitant rise in food allergy and insights into the skin barrier function has highlighted the role of nutrition and diet in the prevention and modification of allergic disorders. Furthermore, the identification of the skin as an important route of sensitization, and the risk of progression to asthma later in life, stress the significance of optimizing our management of skin inflammation in the prevention of allergies. Many nutritional factors, including the type of maternal diet during pregnancy, the duration of breastfeeding, the epicutaneous exposure of allergenic food proteins in the first few years of life, the timing of the introduction of complementary foods, the supplementation of vitamins and probiotics/prebiotics during prenatal and early life, have been assessed as potential targets for the prevention of atopy and eczema. Here, we review the latest data addressing prenatal and perinatal nutritional and dietary interventions in the primary prevention of atopic dermatitis. Also, we define knowledge gaps and targets for future research in the prevention of atopic dermatitis.
Thulja Trikamjee; Pasquale Comberiati; Enza D'Auria; Diego Peroni; Gian Vincenzo Zuccotti. Nutritional Factors in the Prevention of Atopic Dermatitis in Children. Frontiers in Pediatrics 2021, 8, 1 .
AMA StyleThulja Trikamjee, Pasquale Comberiati, Enza D'Auria, Diego Peroni, Gian Vincenzo Zuccotti. Nutritional Factors in the Prevention of Atopic Dermatitis in Children. Frontiers in Pediatrics. 2021; 8 ():1.
Chicago/Turabian StyleThulja Trikamjee; Pasquale Comberiati; Enza D'Auria; Diego Peroni; Gian Vincenzo Zuccotti. 2021. "Nutritional Factors in the Prevention of Atopic Dermatitis in Children." Frontiers in Pediatrics 8, no. : 1.
Oral food challenges remain the gold standard for the diagnosis of food allergy. Nevertheless, the allergy workup is based on the presence of a clinical history, which is evocative of an immune‐allergic reaction, and the first assessment is usually the performance of skin prick tests. Based on these results, allergists are used to evaluate the presence of serum‐specific IgE, which are today the most commonly prescribed in vitro test for the evaluation of a possible food allergy. Other in vitro tests include the basophil activation test, that is becoming more and more employed by clinicians and not only by researchers, and the evaluation of serum IgG4, which is still an issue of debate in the allergy community. The present paper reviews the use of these in vitro tests for the diagnosis of food allergy.
Stefania Arasi; Simona Barni; Carla Mastrorilli; Pasquale Comberiati; Fernanda Chiera; Umberto Pelosi; Francesco Paravati; Davide Caimmi. Role of in vitro testing in food allergy. Pediatric Allergy and Immunology 2020, 31, 36 -38.
AMA StyleStefania Arasi, Simona Barni, Carla Mastrorilli, Pasquale Comberiati, Fernanda Chiera, Umberto Pelosi, Francesco Paravati, Davide Caimmi. Role of in vitro testing in food allergy. Pediatric Allergy and Immunology. 2020; 31 (S26):36-38.
Chicago/Turabian StyleStefania Arasi; Simona Barni; Carla Mastrorilli; Pasquale Comberiati; Fernanda Chiera; Umberto Pelosi; Francesco Paravati; Davide Caimmi. 2020. "Role of in vitro testing in food allergy." Pediatric Allergy and Immunology 31, no. S26: 36-38.
Background The epidemiology, clinical course, and outcomes of COVID-19 patients in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically-diagnosed COVID-19 in real-life settings is lacking. Methods We extracted data from the medical records of adult patients who were consecutively admitted for suspected COVID-19 infection in Moscow, between April 8 and May 28, 2020. Results Of the 4261 patients hospitalised for suspected COVID-19, outcomes were available for 3480 patients (median age 56 years (interquartile range 45-66). The commonest comorbidities were hypertension, obesity, chronic cardiac disease and diabetes. Half of the patients (n=1728) had a positive RT-PCR while 1748 were negative on RT-PCR but had clinical symptoms and characteristic CT signs suggestive of COVID-19 infection.No significant differences in frequency of symptoms, laboratory test results and risk factors for in-hospital mortality were found between those exclusively clinically diagnosed or with positive SARS-CoV-2 RT-PCR.In a multivariable logistic regression model the following were associated with in-hospital mortality; older age (per 1 year increase) odds ratio [OR] 1.05 (95% confidence interval (CI) 1.03 - 1.06); male sex (OR 1.71, 1.24 - 2.37); chronic kidney disease (OR 2.99, 1.89 – 4.64); diabetes (OR 2.1, 1.46 - 2.99); chronic cardiac disease (OR 1.78, 1.24 - 2.57) and dementia (OR 2.73, 1.34 – 5.47). Conclusions Age, male sex, and chronic comorbidities were risk factors for in-hospital mortality. The combination of clinical features were sufficient to diagnoseCOVID-19 infection indicating that laboratory testing is not critical in real-life clinical practice.
Daniel Munblit; Nikita A Nekliudov; Polina Bugaeva; Oleg Blyuss; Maria Kislova; Ekaterina Listovskaya; Aysylu Gamirova; Anastasia Shikhaleva; Vladimir Belyaev; Peter Timashev; John O Warner; Pasquale Comberiati; Christian Apfelbacher; Evgenii Bezrukov; Mikhail E Politov; Andrey Yavorovskiy; Ekaterina Bulanova; Natalya Tsareva; Sergey Avdeev; Valentina A Kapustina; Yuri I Pigolkin; Emmanuelle A Dankwa; Christiana Kartsonaki; Mark G Pritchard; Fomin Victor; Andrey A Svistunov; Denis Butnaru; Petr Glybochko; Victor Fomin; Sechenov StopCOVID Research Team; Anna Berbenyuk; Polina Bobkova; Semyon Bordyugov; Aleksandra Borisenko; Ekaterina Bugaiskaya; Olesya Druzhkova; Dmitry Eliseev; Yasmin El-Taravi; Natalia Gorbova; Elizaveta Gribaleva; Rina Grigoryan; Shabnam Ibragimova; Khadizhat Kabieva; Alena Khrapkova; Natalia Kogut; Karina Kovygina; Margaret Kvaratskheliya; Maria Lobova; Anna Lunicheva; Anastasia Maystrenko; Daria Nikolaeva; Anna Pavlenko; Olga Perekosova; Olga Romanova; Olga Sokova; Veronika Solovieva; Olga Spasskaya; Ekaterina Spiridonova; Olga Sukhodolskaya; Shakir Suleimanov; Nailya Urmantaeva; Olga Usalka; Margarita Zaikina; Anastasia Zorina; Nadezhda Khitrina. StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection. Clinical Infectious Diseases 2020, 1 .
AMA StyleDaniel Munblit, Nikita A Nekliudov, Polina Bugaeva, Oleg Blyuss, Maria Kislova, Ekaterina Listovskaya, Aysylu Gamirova, Anastasia Shikhaleva, Vladimir Belyaev, Peter Timashev, John O Warner, Pasquale Comberiati, Christian Apfelbacher, Evgenii Bezrukov, Mikhail E Politov, Andrey Yavorovskiy, Ekaterina Bulanova, Natalya Tsareva, Sergey Avdeev, Valentina A Kapustina, Yuri I Pigolkin, Emmanuelle A Dankwa, Christiana Kartsonaki, Mark G Pritchard, Fomin Victor, Andrey A Svistunov, Denis Butnaru, Petr Glybochko, Victor Fomin, Sechenov StopCOVID Research Team, Anna Berbenyuk, Polina Bobkova, Semyon Bordyugov, Aleksandra Borisenko, Ekaterina Bugaiskaya, Olesya Druzhkova, Dmitry Eliseev, Yasmin El-Taravi, Natalia Gorbova, Elizaveta Gribaleva, Rina Grigoryan, Shabnam Ibragimova, Khadizhat Kabieva, Alena Khrapkova, Natalia Kogut, Karina Kovygina, Margaret Kvaratskheliya, Maria Lobova, Anna Lunicheva, Anastasia Maystrenko, Daria Nikolaeva, Anna Pavlenko, Olga Perekosova, Olga Romanova, Olga Sokova, Veronika Solovieva, Olga Spasskaya, Ekaterina Spiridonova, Olga Sukhodolskaya, Shakir Suleimanov, Nailya Urmantaeva, Olga Usalka, Margarita Zaikina, Anastasia Zorina, Nadezhda Khitrina. StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection. Clinical Infectious Diseases. 2020; ():1.
Chicago/Turabian StyleDaniel Munblit; Nikita A Nekliudov; Polina Bugaeva; Oleg Blyuss; Maria Kislova; Ekaterina Listovskaya; Aysylu Gamirova; Anastasia Shikhaleva; Vladimir Belyaev; Peter Timashev; John O Warner; Pasquale Comberiati; Christian Apfelbacher; Evgenii Bezrukov; Mikhail E Politov; Andrey Yavorovskiy; Ekaterina Bulanova; Natalya Tsareva; Sergey Avdeev; Valentina A Kapustina; Yuri I Pigolkin; Emmanuelle A Dankwa; Christiana Kartsonaki; Mark G Pritchard; Fomin Victor; Andrey A Svistunov; Denis Butnaru; Petr Glybochko; Victor Fomin; Sechenov StopCOVID Research Team; Anna Berbenyuk; Polina Bobkova; Semyon Bordyugov; Aleksandra Borisenko; Ekaterina Bugaiskaya; Olesya Druzhkova; Dmitry Eliseev; Yasmin El-Taravi; Natalia Gorbova; Elizaveta Gribaleva; Rina Grigoryan; Shabnam Ibragimova; Khadizhat Kabieva; Alena Khrapkova; Natalia Kogut; Karina Kovygina; Margaret Kvaratskheliya; Maria Lobova; Anna Lunicheva; Anastasia Maystrenko; Daria Nikolaeva; Anna Pavlenko; Olga Perekosova; Olga Romanova; Olga Sokova; Veronika Solovieva; Olga Spasskaya; Ekaterina Spiridonova; Olga Sukhodolskaya; Shakir Suleimanov; Nailya Urmantaeva; Olga Usalka; Margarita Zaikina; Anastasia Zorina; Nadezhda Khitrina. 2020. "StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection." Clinical Infectious Diseases , no. : 1.
Background Transition from parent-delivered to self-management is a vulnerable time for adolescents and young adults (AYA) with allergy and asthma. There is currently no European guideline available for healthcare professionals (HCPs) on transition of these patients and local/national protocols are also mostly lacking. Methods European HCPs working with AYA with allergy and asthma were invited to complete an online survey assessing challenges of working with these patients, current transition practices and access to specific healthcare resources. Results A total of 1179 responses from 41 European countries were collected. Most HCPs (86%) reported a lack of a transition guideline and a lack of a transition process (20% paediatric HCPs, 50% of adult HCPs, 56% HCP seeing all ages). Nearly half (48%) acknowledged a lack of an established feedback system between paediatric and adult medical services. Many respondents never routinely asked about mental health issues such as self-harm or depression and are not confident in asking about self-harm (66.6%), sexuality (64%) and depression (43.6%). The majority of HCPs (76%) had not received specific training in the care of AYA although 87% agreed that transition was important for AYA with allergy and asthma. Conclusion Although there was agreement that transition is important for AYA with allergy and asthma, there are crucial limitations and variations in the current provision of transition services across Europe. Standardisation of AYA management and specific training are required. This should improve management and continuity of care during adolescence and into adulthood to achieve the best healthcare outcomes.
Ekaterina Khaleva; Marta Vazquez-Ortiz; Pasquale Comberiati; Audrey DunnGalvin; Helena Pite; Katharina Blumchen; Teresa Garriga-Baraut; Valerie Hox; Alexandra F. Santos; Claudia Gore; Rebecca C. Knibb; Cherry Alviani; Charlotte G. Mortz; Elizabeth Angier; Bettina Duca; Britt Jensen; Silvia Sanchez-Garcia; M. Hazel Gowland; Frans Timmermans; Oliver Pfaar; Graham Roberts. Current transition management of adolescents and young adults with allergy and asthma: a European survey. Clinical and Translational Allergy 2020, 10, 1 -15.
AMA StyleEkaterina Khaleva, Marta Vazquez-Ortiz, Pasquale Comberiati, Audrey DunnGalvin, Helena Pite, Katharina Blumchen, Teresa Garriga-Baraut, Valerie Hox, Alexandra F. Santos, Claudia Gore, Rebecca C. Knibb, Cherry Alviani, Charlotte G. Mortz, Elizabeth Angier, Bettina Duca, Britt Jensen, Silvia Sanchez-Garcia, M. Hazel Gowland, Frans Timmermans, Oliver Pfaar, Graham Roberts. Current transition management of adolescents and young adults with allergy and asthma: a European survey. Clinical and Translational Allergy. 2020; 10 (1):1-15.
Chicago/Turabian StyleEkaterina Khaleva; Marta Vazquez-Ortiz; Pasquale Comberiati; Audrey DunnGalvin; Helena Pite; Katharina Blumchen; Teresa Garriga-Baraut; Valerie Hox; Alexandra F. Santos; Claudia Gore; Rebecca C. Knibb; Cherry Alviani; Charlotte G. Mortz; Elizabeth Angier; Bettina Duca; Britt Jensen; Silvia Sanchez-Garcia; M. Hazel Gowland; Frans Timmermans; Oliver Pfaar; Graham Roberts. 2020. "Current transition management of adolescents and young adults with allergy and asthma: a European survey." Clinical and Translational Allergy 10, no. 1: 1-15.
Background The COVID-19 pandemic has potentially had a negative impact on the mental health and well-being of individuals and families. Anxiety levels and risk factors within particular populations are poorly described. Objective This study aims to evaluate confidence, understanding, trust, concerns, and levels of anxiety during the COVID-19 pandemic in the general population and assess risk factors for increased anxiety. Methods We launched a cross-sectional online survey of a large Russian population between April 6 and 15, 2020, using multiple social media platforms. A set of questions targeted confidence, understanding, trust, and concerns in respondents. The State-Trait Anxiety Inventory was used to measure anxiety. Multiple linear regressions were used to model predictors of COVID-19–related anxiety. Results The survey was completed by 23,756 out of 53,966 (44.0% response rate) unique visitors; of which, 21,364 were residing in 62 areas of Russia. State Anxiety Scale (S-Anxiety) scores were higher than Trait Anxiety Scale scores across all regions of Russia (median S-Anxiety score 52, IQR 44-60), exceeding published norms. Time spent following news on COVID-19 was strongly associated with an increased S-Anxiety adjusted for baseline anxiety level. One to two hours spent reading COVID-19 news was associated with a 5.46 (95% CI 5.03-5.90) point difference, 2-3 hours with a 7.06 (95% CI 6.37-7.74) point difference, and more than three hours with an 8.65 (95% CI 7.82-9.47) point difference, all compared to less than 30 minutes per day. Job loss during the pandemic was another important factor associated with higher S-Anxiety scores (3.95, 95% CI 3.31-4.58). Despite survey respondents reporting high confidence in information regarding COVID-19 as well as an understanding of health care guidance, they reported low overall trust in state and local authorities, and perception of country readiness. Conclusions Among Russian respondents from multiple social media platforms, there was evidence of higher levels of state anxiety associated with recent job loss and increased news consumption, as well as lower than expected trust in government agencies. These findings can help inform the development of key public health messages to help reduce anxiety and raise perceived trust in governmental response to this current national emergency. Using a similar methodology, comparative surveys are ongoing in other national populations.
Nikita A Nekliudov; Oleg Blyuss; Ka Yan Cheung; Loukia Petrou; Jon Genuneit; Nikita Sushentsev; Anna Levadnaya; Pasquale Comberiati; John O Warner; Gareth Tudor-Williams; Martin Teufel; Matthew Greenhawt; Audrey DunnGalvin; Daniel Munblit. Excessive Media Consumption About COVID-19 is Associated With Increased State Anxiety: Outcomes of a Large Online Survey in Russia. Journal of Medical Internet Research 2020, 22, e20955 .
AMA StyleNikita A Nekliudov, Oleg Blyuss, Ka Yan Cheung, Loukia Petrou, Jon Genuneit, Nikita Sushentsev, Anna Levadnaya, Pasquale Comberiati, John O Warner, Gareth Tudor-Williams, Martin Teufel, Matthew Greenhawt, Audrey DunnGalvin, Daniel Munblit. Excessive Media Consumption About COVID-19 is Associated With Increased State Anxiety: Outcomes of a Large Online Survey in Russia. Journal of Medical Internet Research. 2020; 22 (9):e20955.
Chicago/Turabian StyleNikita A Nekliudov; Oleg Blyuss; Ka Yan Cheung; Loukia Petrou; Jon Genuneit; Nikita Sushentsev; Anna Levadnaya; Pasquale Comberiati; John O Warner; Gareth Tudor-Williams; Martin Teufel; Matthew Greenhawt; Audrey DunnGalvin; Daniel Munblit. 2020. "Excessive Media Consumption About COVID-19 is Associated With Increased State Anxiety: Outcomes of a Large Online Survey in Russia." Journal of Medical Internet Research 22, no. 9: e20955.
Asthma is the most frequent chronic disease in children, and its pathogenesis involves genetic, epigenetic, and environmental factors. The rapid rise in the prevalence of asthma registered over the last few decades has stressed the need to identify the environmental and modifiable factors associated with the development of the disease. In particular, there is increasing interest in the role of modifiable nutritional factors specific to both the prenatal and post-natal early life as, during this time, the immune system is particularly vulnerable to exogenous interferences. Several dietary factors, including maternal diet during pregnancy, the duration of breastfeeding, the use of special milk formulas, the timing of the introduction of complementary foods, and prenatal and early life supplementation with vitamins and probiotics/prebiotics, have been addressed as potential targets for the prevention of asthma. In this review, we outline recent findings on the potential role of prenatal and perinatal dietary and nutritional interventions for the primary prevention of pediatric asthma. Moreover, we addressed unmet needs and areas for future research in the prevention of childhood-onset asthma.
Irene Trambusti; Giulia Nuzzi; Giorgio Costagliola; Elvira Verduci; Enza D'Auria; Diego G. Peroni; Pasquale Comberiati. Dietary Interventions and Nutritional Factors in the Prevention of Pediatric Asthma. Frontiers in Pediatrics 2020, 8, 1 .
AMA StyleIrene Trambusti, Giulia Nuzzi, Giorgio Costagliola, Elvira Verduci, Enza D'Auria, Diego G. Peroni, Pasquale Comberiati. Dietary Interventions and Nutritional Factors in the Prevention of Pediatric Asthma. Frontiers in Pediatrics. 2020; 8 ():1.
Chicago/Turabian StyleIrene Trambusti; Giulia Nuzzi; Giorgio Costagliola; Elvira Verduci; Enza D'Auria; Diego G. Peroni; Pasquale Comberiati. 2020. "Dietary Interventions and Nutritional Factors in the Prevention of Pediatric Asthma." Frontiers in Pediatrics 8, no. : 1.
Novel methods in immunological research and microbiome evaluation have dramatically changed several paradigms associated with the pathogenesis of allergic asthma (AAS). Ovalbumin and house dust mite-induced AAS in germ-free or specific pathogen-free mice are the two leading experimental platforms that significantly contribute to elucidate the relationship between AAS and gut microbiota. Beyond the exacerbation of T helper (Th) 2 responses, a complex network of immunological interaction driven by gut microbiota could modulate the final effector phase. Regulatory T cells are abundant in gastrointestinal mucosa and have been shown to be pivotal in AAS. The gut microbiota could also influence the activity of other T cell subsets such as Th9, Th17, and populations of effector/memory T lymphocytes. Furthermore, gut microbiota metabolites drive the hematopoietic pattern of dendritic cells and ameliorate lung Th2 immunity in AAS models. The administration of probiotics has shown conflicting results in AAS, and limited evidence is available on the immunological pathways beyond their activity. Moreover, the impact of early-life gut dysbiosis on AAS is well-known both experimentally and clinically, but discrepancies are observed between preclinical and clinical settings. Herein, our aim is to elucidate the most relevant preclinical and clinical scenarios to enlighten the potential role of the gut microbiota in modulating T lymphocytes activity in AAS.
Alessandro Di Gangi; Maria Elisa Di Cicco; Pasquale Comberiati; Diego G. Peroni. Go With Your Gut: The Shaping of T-Cell Response by Gut Microbiota in Allergic Asthma. Frontiers in Immunology 2020, 11, 1485 .
AMA StyleAlessandro Di Gangi, Maria Elisa Di Cicco, Pasquale Comberiati, Diego G. Peroni. Go With Your Gut: The Shaping of T-Cell Response by Gut Microbiota in Allergic Asthma. Frontiers in Immunology. 2020; 11 ():1485.
Chicago/Turabian StyleAlessandro Di Gangi; Maria Elisa Di Cicco; Pasquale Comberiati; Diego G. Peroni. 2020. "Go With Your Gut: The Shaping of T-Cell Response by Gut Microbiota in Allergic Asthma." Frontiers in Immunology 11, no. : 1485.
Background Fraction exhaled nitric oxide (FeNO) is a non-invasive biomarker of type-2 asthma that can predict response to inhaled corticosteroid(ICS) therapy. Little is known regarding the magnitude of FeNO reduction following an oral corticosteroid(OCS) course and less is known whether there are differential responses based on race in children with mild-to-moderate asthma. Objective To assess the effect of a short course of OCS on FeNO in asthmatic children and to determine if the effect is influenced by race. Methods Children presenting with an acute asthma exacerbation, who had a FeNO measurement within the last six months when clinically stable, were enrolled. Spirometry and FeNO were obtained at the time of exacerbation and following a short course of prednisone. Results 92 children were identified [age 11±3.3years; white,n=46(50%), Hispanics,n=30(33%), AAs,n=16(17%)]. At baseline, AAs were more atopic and had higher mean FeNO values than both white (48.9vs.25.6 ppb;p <.05) and Hispanic children (22.5 ppb;p <.05), despite being prescribed similar ICS doses. During the exacerbation, AAs showed the highest FeNO values, while there was no difference in lung function among the groups. Following prednisone therapy, there was a 56.6% reduction in FeNO, and although AAs maintained the highest FeNO levels, the relative reduction was similar between the groups (53.9%vs.57.8% for AA and non-AA groups, respectively). Conclusion FeNO levels fell over 50% following an OCS course. AA children had a greater degree of type-2 driven airway inflammation at baseline, during an exacerbation and following a short course of OCS compared to non-AAs, although the relative reduction in FeNO was similar between the groups.
Pasquale Comberiati; Diego Peroni; Jonathan Malka-Rais; Riccardo Morganti; Joseph D. Spahn. Fractional exhaled nitric oxide response to oral corticosteroids in children with mild-to-moderate asthma. Annals of Allergy, Asthma & Immunology 2020, 125, 440 -446.e1.
AMA StylePasquale Comberiati, Diego Peroni, Jonathan Malka-Rais, Riccardo Morganti, Joseph D. Spahn. Fractional exhaled nitric oxide response to oral corticosteroids in children with mild-to-moderate asthma. Annals of Allergy, Asthma & Immunology. 2020; 125 (4):440-446.e1.
Chicago/Turabian StylePasquale Comberiati; Diego Peroni; Jonathan Malka-Rais; Riccardo Morganti; Joseph D. Spahn. 2020. "Fractional exhaled nitric oxide response to oral corticosteroids in children with mild-to-moderate asthma." Annals of Allergy, Asthma & Immunology 125, no. 4: 440-446.e1.
Adolescent and young adult (AYA) patients need additional support, while they experience the challenges associated with their age. They need specific training to learn the knowledge and skills required to confidently self‐manage their allergies and/or asthma. Transitional care is a complex process, which should address the psychological, medical, educational and vocational needs of AYA in the developmentally appropriate way. The European Academy of Allergy and Clinical Immunology has developed a clinical practice guideline to provide evidence‐based recommendations for healthcare professionals to support the transitional care of AYA with allergy and/or asthma. This guideline was developed by a multidisciplinary working panel of experts and patient representatives based on two recent systematic reviews. It sets out a series of general recommendations on operating a clinical service for AYA, which include the following: (a) starting transition early (11‐13 years), (b) using a structured, multidisciplinary approach, (c) ensuring AYA fully understand their condition and have resources they can access, (d) active monitoring of adherence and (e) discussing any implications for further education and work. Specific allergy and asthma transition recommendations include (a) simplifying medication regimes and using reminders; (b) focusing on areas where AYA are not confident and involving peers in training AYA patients; (c) identifying and managing psychological and socio‐economic issues impacting disease control and quality of life; (d) enrolling the family in assisting AYA to undertake self‐management; and (e) encouraging AYA to let their friends know about their allergies and asthma. These recommendations may need to be adapted to fit into national healthcare systems.
Graham Roberts; Marta Vazquez‐Ortiz; Rebecca Knibb; Ekaterina Khaleva; Cherry Alviani; Elizabeth Angier; Katharina Blumchen; Pasquale Comberiati; Bettina Duca; Audrey DunnGalvin; Teresa Garriga‐Baraut; Claudia Gore; M. Hazel Gowland; Valerie Hox; Britt Jensen; Charlotte G. Mortz; Oliver Pfaar; Helena Pite; Alexandra F. Santos; Silvia Sanchez‐Garcia; Frans Timmermans. EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy 2020, 75, 2734 -2752.
AMA StyleGraham Roberts, Marta Vazquez‐Ortiz, Rebecca Knibb, Ekaterina Khaleva, Cherry Alviani, Elizabeth Angier, Katharina Blumchen, Pasquale Comberiati, Bettina Duca, Audrey DunnGalvin, Teresa Garriga‐Baraut, Claudia Gore, M. Hazel Gowland, Valerie Hox, Britt Jensen, Charlotte G. Mortz, Oliver Pfaar, Helena Pite, Alexandra F. Santos, Silvia Sanchez‐Garcia, Frans Timmermans. EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy. 2020; 75 (11):2734-2752.
Chicago/Turabian StyleGraham Roberts; Marta Vazquez‐Ortiz; Rebecca Knibb; Ekaterina Khaleva; Cherry Alviani; Elizabeth Angier; Katharina Blumchen; Pasquale Comberiati; Bettina Duca; Audrey DunnGalvin; Teresa Garriga‐Baraut; Claudia Gore; M. Hazel Gowland; Valerie Hox; Britt Jensen; Charlotte G. Mortz; Oliver Pfaar; Helena Pite; Alexandra F. Santos; Silvia Sanchez‐Garcia; Frans Timmermans. 2020. "EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma." Allergy 75, no. 11: 2734-2752.
In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome–related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19–related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease.
Carmen Riggioni; Pasquale Comberiati; Mattia Giovannini; Ioana Agache; Mübeccel Akdis; Magna Alves‐Correia; Josep M. Antó; Alessandra Arcolaci; Ahmet Kursat Azkur; Dilek Azkur; Burcin Beken; Cristina Boccabella; Jean Bousquet; Heimo Breiteneder; Daniela Carvalho; Leticia De Las Vecillas; Zuzana Diamant; Ibon Eguiluz‐Gracia; Thomas Eiwegger; Stefanie Eyerich; Wytske Fokkens; Ya‐Dong Gao; Farah Hannachi; Sebastian L. Johnston; Marek Jutel; Aspasia Karavelia; Ludger Klimek; Beatriz Moya; Kari C. Nadeau; Robyn O'Hehir; Liam O'mahony; Oliver Pfaar; Marek Sanak; Jürgen Schwarze; Milena Sokolowska; María J. Torres; Willem Van De Veen; Menno C. Van Zelm; De Yun Wang; Luo Zhang; Rodrigo Jiménez‐Saiz; Cezmi A. Akdis. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2. Allergy 2020, 75, 2503 -2541.
AMA StyleCarmen Riggioni, Pasquale Comberiati, Mattia Giovannini, Ioana Agache, Mübeccel Akdis, Magna Alves‐Correia, Josep M. Antó, Alessandra Arcolaci, Ahmet Kursat Azkur, Dilek Azkur, Burcin Beken, Cristina Boccabella, Jean Bousquet, Heimo Breiteneder, Daniela Carvalho, Leticia De Las Vecillas, Zuzana Diamant, Ibon Eguiluz‐Gracia, Thomas Eiwegger, Stefanie Eyerich, Wytske Fokkens, Ya‐Dong Gao, Farah Hannachi, Sebastian L. Johnston, Marek Jutel, Aspasia Karavelia, Ludger Klimek, Beatriz Moya, Kari C. Nadeau, Robyn O'Hehir, Liam O'mahony, Oliver Pfaar, Marek Sanak, Jürgen Schwarze, Milena Sokolowska, María J. Torres, Willem Van De Veen, Menno C. Van Zelm, De Yun Wang, Luo Zhang, Rodrigo Jiménez‐Saiz, Cezmi A. Akdis. A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2. Allergy. 2020; 75 (10):2503-2541.
Chicago/Turabian StyleCarmen Riggioni; Pasquale Comberiati; Mattia Giovannini; Ioana Agache; Mübeccel Akdis; Magna Alves‐Correia; Josep M. Antó; Alessandra Arcolaci; Ahmet Kursat Azkur; Dilek Azkur; Burcin Beken; Cristina Boccabella; Jean Bousquet; Heimo Breiteneder; Daniela Carvalho; Leticia De Las Vecillas; Zuzana Diamant; Ibon Eguiluz‐Gracia; Thomas Eiwegger; Stefanie Eyerich; Wytske Fokkens; Ya‐Dong Gao; Farah Hannachi; Sebastian L. Johnston; Marek Jutel; Aspasia Karavelia; Ludger Klimek; Beatriz Moya; Kari C. Nadeau; Robyn O'Hehir; Liam O'mahony; Oliver Pfaar; Marek Sanak; Jürgen Schwarze; Milena Sokolowska; María J. Torres; Willem Van De Veen; Menno C. Van Zelm; De Yun Wang; Luo Zhang; Rodrigo Jiménez‐Saiz; Cezmi A. Akdis. 2020. "A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2." Allergy 75, no. 10: 2503-2541.
Background Hyaluronic acid (HA) is major physiological component of the extracellular matrix, which, in its high molecular weight form (HMW‐HA) has anti‐inflammatory properties. The diffusion of many different medical devices for inhalation therapy containing HA has led to an increase in their prescription, also in children. Here, we systematically review the published evidence on the efficacy and safety of HA for the treatment of upper and lower airway diseases in childhood. Methods Relevant published studies (randomized controlled trials) for the efficacy of HA inhalation in children with upper airways diseases, asthma, cystic fibrosis (CF), and non‐CF bronchiectasis were searched in Pubmed, Scopus, and Web of Knowledge databases by combining the adequate Medical Subject Headings terms and keywords, with no limit for the year of publication. Results We identified seven relevant publications for upper airways diseases, one for asthma, and five for CF, while we found no clinical trial including children with non‐CF bronchiectasis. Meta‐analysis was not conducted due to the heterogeneity of the included studies. Conclusions The evidence of HA efficacy in the treatment of the upper and lower airways is still limited in children. Available data suggest that inhaled HMW‐HA could be useful in the treatment of recurrent upper respiratory infections and chronic or recurrent inflammation of the middle ear and adenoids as well as of the lower airways in cystic fibrosis in association with hypertonic saline solution. Studies on larger populations and on the different formulations and nebulization methods, especially in pediatric age, are urgently needed.
Maria Di Cicco; Diego Peroni; Margherita Sepich; Maria Giulia Tozzi; Pasquale Comberiati; Renato Cutrera. Hyaluronic acid for the treatment of airway diseases in children: Little evidence for few indications. Pediatric Pulmonology 2020, 55, 1 .
AMA StyleMaria Di Cicco, Diego Peroni, Margherita Sepich, Maria Giulia Tozzi, Pasquale Comberiati, Renato Cutrera. Hyaluronic acid for the treatment of airway diseases in children: Little evidence for few indications. Pediatric Pulmonology. 2020; 55 (8):1.
Chicago/Turabian StyleMaria Di Cicco; Diego Peroni; Margherita Sepich; Maria Giulia Tozzi; Pasquale Comberiati; Renato Cutrera. 2020. "Hyaluronic acid for the treatment of airway diseases in children: Little evidence for few indications." Pediatric Pulmonology 55, no. 8: 1.
BACKGROUND The COVID-19 pandemic has potentially had a negative impact on the mental health and well-being of individuals and families. Anxiety levels and risk factors within particular populations are poorly described. OBJECTIVE This study aims to evaluate confidence, understanding, trust, concerns, and levels of anxiety during the COVID-19 pandemic in the general population and assess risk factors for increased anxiety. METHODS We launched a cross-sectional online survey of a large Russian population between April 6 and 15, 2020, using multiple social media platforms. A set of questions targeted confidence, understanding, trust, and concerns in respondents. The State-Trait Anxiety Inventory was used to measure anxiety. Multiple linear regressions were used to model predictors of COVID-19–related anxiety. RESULTS The survey was completed by 23,756 out of 53,966 (44.0% response rate) unique visitors; of which, 21,364 were residing in 62 areas of Russia. State Anxiety Scale (S-Anxiety) scores were higher than Trait Anxiety Scale scores across all regions of Russia (median S-Anxiety score 52, IQR 44-60), exceeding published norms. Time spent following news on COVID-19 was strongly associated with an increased S-Anxiety adjusted for baseline anxiety level. One to two hours spent reading COVID-19 news was associated with a 5.46 (95% CI 5.03-5.90) point difference, 2-3 hours with a 7.06 (95% CI 6.37-7.74) point difference, and more than three hours with an 8.65 (95% CI 7.82-9.47) point difference, all compared to less than 30 minutes per day. Job loss during the pandemic was another important factor associated with higher S-Anxiety scores (3.95, 95% CI 3.31-4.58). Despite survey respondents reporting high confidence in information regarding COVID-19 as well as an understanding of health care guidance, they reported low overall trust in state and local authorities, and perception of country readiness. CONCLUSIONS Among Russian respondents from multiple social media platforms, there was evidence of higher levels of state anxiety associated with recent job loss and increased news consumption, as well as lower than expected trust in government agencies. These findings can help inform the development of key public health messages to help reduce anxiety and raise perceived trust in governmental response to this current national emergency. Using a similar methodology, comparative surveys are ongoing in other national populations.
Nikita A Nekliudov; Oleg Blyuss; Ka Yan Cheung; Loukia Petrou; Jon Genuneit; Nikita Sushentsev; Anna Levadnaya; Pasquale Comberiati; John O Warner; Gareth Tudor-Williams; Martin Teufel; Matthew Greenhawt; Audrey Dunn Galvin; Daniel Munblit. Excessive Media Consumption About COVID-19 is Associated With Increased State Anxiety: Outcomes of a Large Online Survey in Russia (Preprint). 2020, 1 .
AMA StyleNikita A Nekliudov, Oleg Blyuss, Ka Yan Cheung, Loukia Petrou, Jon Genuneit, Nikita Sushentsev, Anna Levadnaya, Pasquale Comberiati, John O Warner, Gareth Tudor-Williams, Martin Teufel, Matthew Greenhawt, Audrey Dunn Galvin, Daniel Munblit. Excessive Media Consumption About COVID-19 is Associated With Increased State Anxiety: Outcomes of a Large Online Survey in Russia (Preprint). . 2020; ():1.
Chicago/Turabian StyleNikita A Nekliudov; Oleg Blyuss; Ka Yan Cheung; Loukia Petrou; Jon Genuneit; Nikita Sushentsev; Anna Levadnaya; Pasquale Comberiati; John O Warner; Gareth Tudor-Williams; Martin Teufel; Matthew Greenhawt; Audrey Dunn Galvin; Daniel Munblit. 2020. "Excessive Media Consumption About COVID-19 is Associated With Increased State Anxiety: Outcomes of a Large Online Survey in Russia (Preprint)." , no. : 1.
Allergen immunotherapy is a cornerstone in the treatment of allergic children. The clinical efficiency relies on a well‐defined immunologic mechanism promoting regulatory T cells and downplaying the immune response induced by allergens. Clinical indications have been well documented for respiratory allergy in the presence of rhinitis and/or allergic asthma, to pollens and dust mites. Patients who have had an anaphylactic reaction to hymenoptera venom are also good candidates for allergen immunotherapy. Administration of allergen is currently mostly either by subcutaneous injections or by sublingual administration. Both methods have been extensively studied and have pros and cons. Specifically in children, the choice of the method of administration according to the patient's profile is important. Although allergen immunotherapy is widely used, there is a need for improvement. More particularly, biomarkers for prediction of the success of the treatments are needed. The strength and efficiency of the immune response may also be boosted by the use of better adjuvants. Finally, novel formulations might be more efficient and might improve the patient's adherence to the treatment. This user's guide reviews current knowledge and aims to provide clinical guidance to healthcare professionals taking care of children undergoing allergen immunotherapy.
Montserrat Alvaro‐Lozano; Cezmi A. Akdis; Mubeccel Akdis; Cherry Alviani; Elisabeth Angier; Stefania Arasi; Lisa Arzt‐Gradwohl; Domingo Barber; Raphaëlle Bazire; Ozlem Cavkaytar; Pasquale Comberiati; Stephanie Dramburg; Stephen R. Durham; Aarif Eifan; Leandra Forchert; Susanne Halken; Max Kirtland; Umut C. Kucuksezer; Janice A. Layhadi; Paolo Maria Matricardi; Antonella Muraro; Cevdet Ozdemir; Giovanni Battista Pajno; Oliver Pfaar; Ekaterina Potapova; Carmen Riggioni; Graham Roberts; Pablo Rodriguez del Rio; Mohamed H. Shamji; Gunter J. Sturm; Marta Vazquez‐Ortiz. Allergen Immunotherapy in Children User’s Guide. Pediatric Allergy and Immunology 2020, 31, 1 -101.
AMA StyleMontserrat Alvaro‐Lozano, Cezmi A. Akdis, Mubeccel Akdis, Cherry Alviani, Elisabeth Angier, Stefania Arasi, Lisa Arzt‐Gradwohl, Domingo Barber, Raphaëlle Bazire, Ozlem Cavkaytar, Pasquale Comberiati, Stephanie Dramburg, Stephen R. Durham, Aarif Eifan, Leandra Forchert, Susanne Halken, Max Kirtland, Umut C. Kucuksezer, Janice A. Layhadi, Paolo Maria Matricardi, Antonella Muraro, Cevdet Ozdemir, Giovanni Battista Pajno, Oliver Pfaar, Ekaterina Potapova, Carmen Riggioni, Graham Roberts, Pablo Rodriguez del Rio, Mohamed H. Shamji, Gunter J. Sturm, Marta Vazquez‐Ortiz. Allergen Immunotherapy in Children User’s Guide. Pediatric Allergy and Immunology. 2020; 31 (S25):1-101.
Chicago/Turabian StyleMontserrat Alvaro‐Lozano; Cezmi A. Akdis; Mubeccel Akdis; Cherry Alviani; Elisabeth Angier; Stefania Arasi; Lisa Arzt‐Gradwohl; Domingo Barber; Raphaëlle Bazire; Ozlem Cavkaytar; Pasquale Comberiati; Stephanie Dramburg; Stephen R. Durham; Aarif Eifan; Leandra Forchert; Susanne Halken; Max Kirtland; Umut C. Kucuksezer; Janice A. Layhadi; Paolo Maria Matricardi; Antonella Muraro; Cevdet Ozdemir; Giovanni Battista Pajno; Oliver Pfaar; Ekaterina Potapova; Carmen Riggioni; Graham Roberts; Pablo Rodriguez del Rio; Mohamed H. Shamji; Gunter J. Sturm; Marta Vazquez‐Ortiz. 2020. "Allergen Immunotherapy in Children User’s Guide." Pediatric Allergy and Immunology 31, no. S25: 1-101.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin disease, affecting up to 25% of children. Topical corticosteroids (TCS) are currently used as first-line antiinflammatory treatment for AD, due to their overall therapeutic efficacy, and the availability of different potency classes and a wide array of formulations. Therapeutic efficacy of TCS depends upon selecting the appropriate vehicle and potency, and the frequency of application, also taking into account the duration of treatment and patient preferences. This article focuses on TCS benefits and potential risks and it provides practical tips to properly use these drugs in clinical practice, to make a patient-tailored treatment approach.
Andrea Chiricozzi; Pasquale Comberiati; Enza D’Auria; Gianvincenzo Zuccotti; Diego G. Peroni. Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice. Pharmacological Research 2020, 158, 104878 .
AMA StyleAndrea Chiricozzi, Pasquale Comberiati, Enza D’Auria, Gianvincenzo Zuccotti, Diego G. Peroni. Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice. Pharmacological Research. 2020; 158 ():104878.
Chicago/Turabian StyleAndrea Chiricozzi; Pasquale Comberiati; Enza D’Auria; Gianvincenzo Zuccotti; Diego G. Peroni. 2020. "Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice." Pharmacological Research 158, no. : 104878.